Retatrutide_10mg

Retatrutide (LY3437943) is an experimental weight-loss medication developed by Eli Lilly, currently undergoing Phase 3 clinical trials. This triple receptor agonist targets GLP-1, GIP, and glucagon receptors, aiming to regulate appetite, enhance fat burning, and improve metabolic health.

In Phase 2 studies, retatrutide demonstrated significant efficacy, with participants losing up to 24.2% of their body weight over 48 weeks. The 10 mg dose has been particularly effective in reducing body weight and improving metabolic markers. Additionally, retatrutide has shown promise in managing conditions like type 2 diabetes and nonalcoholic fatty liver disease